CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 11:04 AM ET
CytomX Therapeutics Inc (CTMX) Financials: Revenue, Profit and Cash Flow
CytomX Therapeutics reported revenue of $76.20M for the fiscal year ended Dec 31, 2025, down 44.8% from the year before. That year, net income was -$17.37M with a net margin of -22.8%, operating cash flow was -$75.59M and free cash flow was -$75.81M. The quarter ended Sep 30, 2026 had revenue of $1.69M and net income of -$20.00M.
Revenue and Margins
The operating margin was -29.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $15.04M, a compound annual rate of 19.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $76.20M | -44.8% | 100.0% | -29.3% | -22.8% |
| Dec 2024 | $138.10M | +36.4% | 100.0% | 18.1% | 23.1% |
| Dec 2023 | $101.21M | +90.4% | 100.0% | -6.4% | -0.6% |
| Dec 2022 | $53.16M | +42.5% | 100.0% | -190.6% | -186.8% |
| Dec 2021 | $37.31M | -45.5% | 100.0% | -311.0% | -310.5% |
| Dec 2020 | $68.43M | +154.4% | 100.0% | -117.7% | -94.7% |
| Dec 2019 | $26.90M | -54.8% | 100.0% | -525.9% | -493.7% |
| Dec 2018 | $59.50M | -16.9% | 100.0% | -130.9% | -142.2% |
| Dec 2017 | $71.62M | +376.1% | 100.0% | -64.6% | -60.2% |
| Dec 2016 | $15.04M | N/A | 100.0% | -396.1% | -391.5% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $26.90M | $59.50M | $71.62M | $15.04M |
| Gross profit | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $26.90M | $59.50M | $71.62M | $15.04M |
| Research and development | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M | $131.62M | $103.87M | $92.28M | $54.76M |
| Operating income | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M | -$80.54M | -$141.48M | -$77.87M | -$46.26M | -$59.59M |
| Net income | -$17.37M | $31.87M | -$569.00K | -$99.32M | -$115.87M | -$64.82M | -$132.82M | -$84.60M | -$43.10M | -$58.90M |
| EBITDA | N/A | N/A | N/A | -$98.60M | -$113.15M | -$78.23M | -$141.24M | -$77.76M | -$44.25M | -$56.26M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.69M | $1.42M | $10.26M | $663.00K | $5.96M | $18.66M | $50.92M | $38.09M | $33.43M | $25.11M | $41.46M | $26.61M |
| Gross profit | $1.69M | $1.42M | $10.26M | $663.00K | $5.96M | $18.66M | $50.92M | $38.09M | $33.43M | $25.11M | $41.46M | $26.61M |
| Operating income | -$23.50M | -$23.78M | -$19.67M | -$27.93M | -$15.77M | -$1.29M | $22.62M | $17.68M | $4.11M | -$8.45M | $11.66M | -$606.00K |
| Net income | -$20.00M | -$20.67M | -$18.25M | -$26.51M | -$14.23M | -$154.00K | $23.52M | $18.88M | $5.74M | -$6.53M | $13.79M | $837.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $4.24M by $8.43M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M | $341.28M | $457.11M | $397.64M | $199.13M |
| Current assets | $143.92M | $107.31M | $182.94M | $237.10M | $310.30M | $324.01M | $303.33M | $445.48M | $388.60M | $188.15M |
| Cash and equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M | $188.43M | $247.58M | $177.55M | $104.64M |
| Total liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $339.87M | $366.44M | $290.17M | $326.23M | $327.75M | $120.65M |
| Short-term debt | $4.24M | $5.14M | $4.59M | $4.08M | $3.62M | $3.19M | $2.81M | $13.34M | N/A | N/A |
| Shareholder equity | $99.01M | -$456.00K | -$47.45M | -$85.75M | -$459.00K | -$7.77M | $51.11M | $130.88M | $69.90M | $78.48M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $364.68M | $381.23M | $359.36M | $151.57M | $158.25M | $175.06M | $98.50M | $120.53M | $138.98M | $159.22M | $184.69M | $201.79M |
| Total liabilities | $79.79M | $79.16M | $39.41M | $52.56M | $50.87M | $55.15M | $73.45M | $120.99M | $162.43M | $190.45M | $216.37M | $249.24M |
| Cash and equivalents | $33.96M | $17.22M | $28.83M | $12.67M | $34.19M | $49.04M | $47.60M | $38.05M | $40.58M | $43.25M | $36.19M | $17.17M |
| Shareholder equity | $284.89M | $302.07M | $319.94M | $99.01M | $107.39M | $119.91M | $25.05M | -$456.00K | -$23.45M | -$31.23M | -$31.68M | -$47.45M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.59M | -$86.23M | -$56.03M | -$110.79M | -$119.03M | $5.26M | -$140.48M | -$75.52M | $170.37M | -$2.03M |
| Capital expenditures | $220.00K | $310.00K | $840.00K | $1.74M | $1.61M | $2.31M | $3.50M | $3.79M | $1.56M | $2.18M |
| Free cash flow | -$75.81M | -$86.54M | -$56.88M | -$112.53M | -$120.64M | $2.95M | -$143.98M | -$79.31M | $168.81M | -$4.21M |
| Dividends paid | $3.00M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $12.00K |
| Investing cash flow | -$59.74M | $99.70M | -$150.67M | $98.26M | $22.49M | -$18.72M | $79.70M | $5.93M | -$121.27M | $45.86M |
| Financing cash flow | $110.45M | $7.52M | $30.23M | $648.00K | $110.21M | $16.89M | $1.63M | $139.62M | $23.80M | $996.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.65M | -$18.07M | -$25.55M | -$23.24M | -$15.55M | -$15.75M | -$21.04M | -$19.91M | -$20.73M | -$19.55M | -$26.05M | -$21.96M |
| Capital expenditures | $589.00K | N/A | $0 | $201.00K | $127.00K | $27.00K | $119.00K | $80.00K | $19.00K | $96.00K | $115.00K | $266.00K |
| Free cash flow | $16.06M | N/A | -$25.55M | -$23.44M | -$15.68M | -$15.78M | -$21.16M | -$19.99M | -$20.75M | -$19.64M | -$26.16M | -$22.23M |
Frequently Asked Questions About CTMX
What is CytomX Therapeutics' annual revenue?
CytomX Therapeutics reported revenue of $76.20M for the fiscal year ended Dec 31, 2025.
How fast is CytomX Therapeutics' revenue growing?
Revenue was down 44.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.8%.
Is CytomX Therapeutics profitable?
No. CytomX Therapeutics reported net income of -$17.37M for the fiscal year ended Dec 31, 2025, with a net margin of -22.8%.
How much free cash flow does CTMX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$75.59M minus capital expenditures of $220.00K produced free cash flow of -$75.81M.
How much debt does CytomX Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $4.24M and cash and equivalents of $12.67M.
CTMX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors